CN106999569B - 肠道病毒灭活的改进的方法、佐剂吸附及其获得的剂量减少的疫苗组合物 - Google Patents

肠道病毒灭活的改进的方法、佐剂吸附及其获得的剂量减少的疫苗组合物 Download PDF

Info

Publication number
CN106999569B
CN106999569B CN201580066368.0A CN201580066368A CN106999569B CN 106999569 B CN106999569 B CN 106999569B CN 201580066368 A CN201580066368 A CN 201580066368A CN 106999569 B CN106999569 B CN 106999569B
Authority
CN
China
Prior art keywords
poliovirus
type
dose
particles
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580066368.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN106999569A (zh
Inventor
R·M·迪尔
S·S·皮索尔
J·K·扎德
R·N·沙伯尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serum Institute of India Pvt Ltd
Original Assignee
Serum Institute of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute of India Pvt Ltd filed Critical Serum Institute of India Pvt Ltd
Priority to CN202110677385.5A priority Critical patent/CN113368227A/zh
Publication of CN106999569A publication Critical patent/CN106999569A/zh
Application granted granted Critical
Publication of CN106999569B publication Critical patent/CN106999569B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32661—Methods of inactivation or attenuation
    • C12N2770/32663—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32671—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580066368.0A 2014-10-07 2015-10-06 肠道病毒灭活的改进的方法、佐剂吸附及其获得的剂量减少的疫苗组合物 Active CN106999569B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110677385.5A CN113368227A (zh) 2014-10-07 2015-10-06 肠道病毒灭活的改进的方法、佐剂吸附及其获得的剂量减少的疫苗组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3180MU2014 2014-10-07
IN3180/MUM/2014 2014-10-07
PCT/IN2015/000376 WO2016063291A1 (en) 2014-10-07 2015-10-06 Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110677385.5A Division CN113368227A (zh) 2014-10-07 2015-10-06 肠道病毒灭活的改进的方法、佐剂吸附及其获得的剂量减少的疫苗组合物

Publications (2)

Publication Number Publication Date
CN106999569A CN106999569A (zh) 2017-08-01
CN106999569B true CN106999569B (zh) 2021-06-29

Family

ID=55300742

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580066368.0A Active CN106999569B (zh) 2014-10-07 2015-10-06 肠道病毒灭活的改进的方法、佐剂吸附及其获得的剂量减少的疫苗组合物
CN202110677385.5A Pending CN113368227A (zh) 2014-10-07 2015-10-06 肠道病毒灭活的改进的方法、佐剂吸附及其获得的剂量减少的疫苗组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110677385.5A Pending CN113368227A (zh) 2014-10-07 2015-10-06 肠道病毒灭活的改进的方法、佐剂吸附及其获得的剂量减少的疫苗组合物

Country Status (24)

Country Link
US (1) US10485862B2 (cg-RX-API-DMAC10.html)
EP (2) EP3663396A1 (cg-RX-API-DMAC10.html)
JP (2) JP6755243B2 (cg-RX-API-DMAC10.html)
KR (2) KR102510744B1 (cg-RX-API-DMAC10.html)
CN (2) CN106999569B (cg-RX-API-DMAC10.html)
AU (2) AU2015334495B2 (cg-RX-API-DMAC10.html)
CA (1) CA2963897C (cg-RX-API-DMAC10.html)
CU (1) CU24510B1 (cg-RX-API-DMAC10.html)
CY (1) CY1123078T1 (cg-RX-API-DMAC10.html)
DK (1) DK3204494T3 (cg-RX-API-DMAC10.html)
EA (1) EA201700187A1 (cg-RX-API-DMAC10.html)
ES (1) ES2803578T3 (cg-RX-API-DMAC10.html)
HU (1) HUE049104T2 (cg-RX-API-DMAC10.html)
LT (1) LT3204494T (cg-RX-API-DMAC10.html)
MX (1) MX388525B (cg-RX-API-DMAC10.html)
MY (1) MY204389A (cg-RX-API-DMAC10.html)
PE (1) PE20171132A1 (cg-RX-API-DMAC10.html)
PH (1) PH12017500627A1 (cg-RX-API-DMAC10.html)
PL (1) PL3204494T3 (cg-RX-API-DMAC10.html)
PT (1) PT3204494T (cg-RX-API-DMAC10.html)
SG (2) SG10202010814RA (cg-RX-API-DMAC10.html)
SI (1) SI3204494T1 (cg-RX-API-DMAC10.html)
UA (1) UA125788C2 (cg-RX-API-DMAC10.html)
WO (1) WO2016063291A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY204389A (en) * 2014-10-07 2024-08-27 Serum Institute Of India Pvt Ltd Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
US11141475B2 (en) 2016-05-10 2021-10-12 Najit Technologies, Inc. Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
CA3032901A1 (en) * 2016-08-26 2018-03-01 Serum Institute Of India Private Limited Multivalent vaccine composition
TWI711700B (zh) * 2017-07-10 2020-12-01 印度商印度血清研究公司 使腸病毒去活化之改良方法、佐劑吸附及所獲得之劑量減少的疫苗組成物
MY202505A (en) 2017-11-03 2024-05-01 Takeda Vaccines Inc Zika vaccines and immunogenic compositions, and methods of using the same
SG11202003975WA (en) 2017-11-30 2020-06-29 Takeda Vaccines Inc Method for inactivating zika virus and related methods
EP3749757A4 (en) * 2018-02-07 2021-11-24 Bharat Biotech International Limited PROCESS FOR PURIFICATION AND INACTIVATION OF ENTERVIRUSES AND VACCINE COMPOSITIONS OBTAINED THEREOF
CN109550046B (zh) * 2018-12-21 2020-08-25 北京民海生物科技有限公司 一种吸附无细胞百白破-脊髓灰质炎-b型流感嗜血杆菌联合疫苗及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1977970A (zh) * 2006-12-06 2007-06-13 云南沃森生物技术有限公司 一种混合床凝胶过滤层析技术用于病毒性疫苗纯化的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU714493B2 (en) * 1996-07-02 2000-01-06 Connaught Laboratories Limited Multivalent DTP-polio vaccines
RS20070078A (sr) * 2004-08-27 2008-11-28 Panacea Biotec Ltd., Inaktivirana vakcina protiv poliomijelitisa nastala iz sabinovog soja polio virusa
CN1647822A (zh) * 2005-02-06 2005-08-03 北京生物制品研究所 脊髓灰质炎灭活疫苗及其制备方法
SI2097102T1 (sl) 2006-09-07 2012-09-28 Glaxosmithkline Biolog Sa Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
BR112012014689B1 (pt) * 2009-12-16 2019-11-12 Serum Institute Of India Private Limited composição imunogênica
CN103533954B (zh) * 2011-03-02 2015-09-09 诺华股份有限公司 含较低剂量的抗原和/或佐剂的联合疫苗
GB201105981D0 (en) * 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
MY204389A (en) * 2014-10-07 2024-08-27 Serum Institute Of India Pvt Ltd Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1977970A (zh) * 2006-12-06 2007-06-13 云南沃森生物技术有限公司 一种混合床凝胶过滤层析技术用于病毒性疫苗纯化的方法

Also Published As

Publication number Publication date
MY204389A (en) 2024-08-27
CU20170044A7 (es) 2018-09-05
UA125788C2 (uk) 2022-06-08
DK3204494T3 (da) 2020-07-06
CU24510B1 (es) 2021-05-12
LT3204494T (lt) 2020-07-10
EP3204494A1 (en) 2017-08-16
AU2015334495A1 (en) 2017-05-25
EP3663396A1 (en) 2020-06-10
EP3204494B1 (en) 2020-04-01
PT3204494T (pt) 2020-07-10
NZ731341A (en) 2023-11-24
PH12017500627A1 (en) 2017-09-25
MX388525B (es) 2025-03-20
BR112017007089A2 (pt) 2017-12-26
AU2021269395A1 (en) 2021-12-16
JP7063957B2 (ja) 2022-05-09
CA2963897A1 (en) 2016-04-28
KR102219638B1 (ko) 2021-02-23
JP2017533899A (ja) 2017-11-16
PE20171132A1 (es) 2017-08-09
KR20170063947A (ko) 2017-06-08
JP2020203906A (ja) 2020-12-24
PL3204494T3 (pl) 2020-09-21
CN106999569A (zh) 2017-08-01
SI3204494T1 (sl) 2020-08-31
SG11201702838SA (en) 2017-05-30
SG10202010814RA (en) 2020-12-30
CY1123078T1 (el) 2021-10-29
AU2015334495B2 (en) 2021-08-19
EA201700187A1 (ru) 2017-12-29
MX2017004534A (es) 2017-10-11
ES2803578T3 (es) 2021-01-28
US20170348411A1 (en) 2017-12-07
KR102510744B1 (ko) 2023-03-15
US10485862B2 (en) 2019-11-26
JP6755243B2 (ja) 2020-09-16
CN113368227A (zh) 2021-09-10
KR20210021148A (ko) 2021-02-24
CA2963897C (en) 2023-08-22
AU2021269395B2 (en) 2024-05-23
HUE049104T2 (hu) 2020-08-28
WO2016063291A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
JP7063957B2 (ja) エンテロウイルス不活化およびアジュバント吸着のための改良された方法、ならびに、それから得られる投与量減量ワクチン組成物
CN103442730B (zh) 组合七价疫苗
RU2641969C2 (ru) Множественная вакцинация, включающая менингококки серогруппы с
RU2634393C2 (ru) Комбинированная вакцина с ацеллюлярным коклюшем
JP2017533899A5 (cg-RX-API-DMAC10.html)
EP2529750A1 (en) Combination vaccine with whole cell pertussis
JP2021181445A (ja) 多価ワクチン組成物
ES2560452T3 (es) Vacuna de IPV-DPT
EP3749757A1 (en) A process for enterovirus purification and inactivation and vaccine compositions obtained thereof
TWI711700B (zh) 使腸病毒去活化之改良方法、佐劑吸附及所獲得之劑量減少的疫苗組成物
US11793869B2 (en) Methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
HK1241920A1 (en) Improved methods for poliovirus inactivation, adjuvant adsorption
HK1241920B (en) Improved methods for poliovirus inactivation, adjuvant adsorption
EA040305B1 (ru) Полиовакцинная композиция со сниженной дозой антигена d и способ ее получения
OA18258A (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof.
BR112017007089B1 (pt) Método para a produção de uma composição compreendendo partículas enterovirais
OA20569A (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20351029